EcoDrugPlus

Activin A Receptor Like Type 1

Ensembl ID : ENSRFEG00010017527
Gene Symbol: ACVRL1
1 Cross references
353 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSRFEG00010020513
Gene Symbol: ACVR2B
1 Cross references
257 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSRFEG00010020201
Gene Symbol: ADORA1
1 Cross references
269 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSRFEG00010014747
Gene Symbol: ADORA2A
1 Cross references
260 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSRFEG00010010507
Gene Symbol: ADORA2B
1 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSRFEG00010005851
Gene Symbol: ADA
1 Cross references
216 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSRFEG00010006218
Gene Symbol: ADRA1A
1 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSRFEG00010018512
Gene Symbol: ADRA1B
1 Cross references
263 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSRFEG00010018678
Gene Symbol: ADRA1D
1 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSRFEG00010011721
Gene Symbol: ADRA2A
1 Cross references
230 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSRFEG00010017415
Gene Symbol: ADRA2B
1 Cross references
219 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSRFEG00010007225
Gene Symbol: ADRA2C
1 Cross references
227 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).